Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK202.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-25.
Status change: Not Yet Recruiting → Recruiting 2025-03-09
Trial Details
NCT Number NCT06707610
Lead Sponsor Shanghai Allink Biotherapeutics Co., Ltd.
Conditions Advanced Cancer, Advanced Solid Tumor
Enrollment 234 participants
Start Date 2025-02-10
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-12